巨子生物(02367)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02367 巨子生物

休市中 05-15 16:09:05

29.320

-0.380

-1.28%

最高29.920	最低29.040	成交量370.86万
今开29.720	昨收29.700	日振幅2.96%
总市值311.38亿	流通市值311.38亿	总股本10.62亿
成交额1.09亿	换手率0.35%	流通股本10.62亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02367","market":"HK","secType":"STK","nameCN":"巨子生物","latestPrice":29.32,"timestamp":1778832545004,"preClose":29.7,"halted":0,"volume":3708556,"delay":0,"changeRate":-0.012794612794612761,"floatShares":1061999999,"shares":1061999999,"eps":2.079931895494804,"marketStatus":"休市中","change":-0.38,"latestTime":"05-15 16:09:05","open":29.72,"high":29.92,"low":29.04,"amount":108526061,"amplitude":0.02963,"askPrice":29.32,"askSize":56200,"bidPrice":29.28,"bidSize":1200,"shortable":3,"etf":0,"ttmEps":2.079931895494804,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779067800000},"marketStatusCode":7,"adr":0,"listingDate":1667491200000,"exchange":"SEHK","adjPreClose":29.7,"dividendRate":0.02112,"openAndCloseTimeList":[[1778808600000,1778817600000],[1778821200000,1778832000000]],"volumeRatio":0.736519,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02367/wiki","defaultTab":"wiki","newsList":[{"id":"2633687104","title":"【券商聚焦】中国银河：医药行业进入复苏周期 CXO板块景气度较高","url":"https://stock-news.laohu8.com/highlight/detail?id=2633687104","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633687104?lang=zh_cn&edition=full","pubTime":"2026-05-08 09:00","pubTimestamp":1778202049,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中国银河证券表示，2025年医药行业上市公司营业收入增长0.4%，归母净利润增长3.9%，扣非净利润下降4.1%，2026年一季度营业收入增长1.1%，归母净利润下降3.2%，扣非净利润增长2.0%。2025全年医药行业收入端小幅微增，主要系医保控费趋严，仿制药、耗材等集采常态化开展导致行业承压。2026年一季度创新药产业链高景气度延续，收入增幅扩大、非经常性损益占比下降，行业整体经营盈利能力提升，进入复苏上行周期。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/ZDNhNDUwNDVmY2U2MTcxMzU2NTcyMzcyOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ZDNhNDUwNDVmY2U2MTcxMzU2NTcyMzcyOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1980878","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CXO","LU0417516738.SGD","LU2476274720.SGD","LU0640798160.USD","LU1303224171.USD","LU1961090484.USD","LU2778985437.USD","09926","LU1251922891.USD","02228","06821","LU0348735423.USD","01099","09688","LU0417516902.SGD","02268","BK1583","LU1719994722.HKD","BK0188","BK1207","BK1500","LU0561508036.HKD","LU1794554557.SGD","LU0588546209.SGD","LU0348766576.USD","06881","LU1969619763.USD","BK1141","03933","LU0417516571.SGD","LU0634319403.HKD","01530","02196","LU2328871848.SGD","BK0276","IE00BPRC5H50.USD","BK1197","06160","LU2488822045.USD","LU0348783233.USD","01789","601881","LU0348767384.USD","HK0000165453.HKD","02367","BK1588","LU0307460666.USD","BK1585","BK1593","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633101233","title":"【券商聚焦】华泰证券：美容护理板块处于“三低”状态 建议积极跟踪618/新品势能等催化剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2633101233","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633101233?lang=zh_cn&edition=full","pubTime":"2026-05-08 08:58","pubTimestamp":1778201918,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华泰证券表示，美容护理板块现处于预期低/估值低/持仓低的“三低”状态，行业面/资金面/基本面等维度的边际改善均有可能带来积极变化。从财报情况来看，部分标的业绩改善迹象已现，复苏节奏和斜率略有差异。整体而言品牌商及医美上游厂商分化明显，代工厂逐步复苏，代运营商转型持续兑现。建议积极跟踪618/新品势能等催化剂，若个股有盈利预测上修潜力，戴维斯双击或可期待。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1980876","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1934453819.USD","BK0028","02367","BK1215","LU0039217434.USD","BK1593","LU1064130708.USD","LU0871576103.HKD","LU1781817850.SGD","LU1808992512.USD","BK1207","BK0183","LU0531971595.HKD","BK0276","01830","LU0164865239.USD","02145","LU1979443071.USD","LU1328615791.USD","LU2242644610.SGD","601688","BK0188","LU2148510915.USD","LU0455707207.USD","LU2488822045.USD","LU1064131003.USD","BK0012","LU0502904849.HKD","LU1580142542.USD","SG9999004311.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170257438","title":"巨子生物授予董事股份回购授权，规模达已发行股本一成","url":"https://stock-news.laohu8.com/highlight/detail?id=1170257438","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170257438?lang=zh_cn&edition=full","pubTime":"2026-05-06 21:40","pubTimestamp":1778074851,"startTime":"0","endTime":"0","summary":"巨子生物控股有限公司于最新公告中披露，将在2026年5月28日召开的股东周年大会上提呈普通决议案，拟向董事会授予回购公司股份的一般性授权，规模最高可达截至股东周年大会当日公司已发行股份总数的10%。该授权若获通过，董事会最多可在香港联交所回购约106,170,400股股份。据公告，股东大会将于2026年5月28日在中国陕西省西安市长安区上林苑七路1855号召开。董事会认为，该计划有助优化公司资本结构和提升股东整体回报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"巨子生物授予董事股份回购授权，规模达已发行股本一成","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1137592575","title":"巨子生物4月股份变动月报：本月购回并注销920万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1137592575","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137592575?lang=zh_cn&edition=full","pubTime":"2026-05-06 21:40","pubTimestamp":1778074845,"startTime":"0","endTime":"0","summary":"巨子生物控股有限公司于2026年5月6日发布2026年4月股份变动月报表，披露了公司在2026年4月的股本及股份变动情况。截至2026年4月30日，公司法定注册股本为5,000,000,000股，面值每股0.00001美元，注册股本金额50,000美元。公司于2026年4月20日依据2025年6月13日股东大会决议进行了股份购回，并已将上述购回的股份予以注销，本月末未持有任何库藏股。截至4月30日，公司已发行股份共1,061,704,000股，仍满足香港联交所要求的最低公众持股比例。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2632589698","title":"可复美再推“大单品” 巨子生物想寻找修复新支点","url":"https://stock-news.laohu8.com/highlight/detail?id=2632589698","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632589698?lang=zh_cn&edition=full","pubTime":"2026-05-01 07:00","pubTimestamp":1777590000,"startTime":"0","endTime":"0","summary":"经历2025年业绩承压后，巨子生物（02367.HK）正在迎来一个新的观察窗口。4月中旬以来，该公司旗下可复美新单品“超透棒”在多个电商平台密集铺开。公开信息显示，该产品上市前后，可复美在微博、抖音、京东等渠道连续预热，并通过明星、达人内容及自营渠道形成新品声量。多家券商渠道跟踪信息显示，可复美超透棒上市后销售爬坡较快。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605013726851714.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605013726851714.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02367","BK1207","SG9999004311.SGD","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631327756","title":"巨子生物(02367.HK)拟委任毕马威为公司新核数师","url":"https://stock-news.laohu8.com/highlight/detail?id=2631327756","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631327756?lang=zh_cn&edition=full","pubTime":"2026-04-30 20:27","pubTimestamp":1777552022,"startTime":"0","endTime":"0","summary":"格隆汇4月30日丨巨子生物(02367.HK)公告，于2026年4月30日，董事会已议决：(1)不再重新委任公司现任核数师安永，因此安永将于应届股东周年大会结束时退任公司核数师；及(2)经公司审核委员会建议，建议委任毕马威为公司新核数师。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260430/32195059.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02367","SG9999004311.SGD","BK1207","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186056667","title":"巨子生物2025年营收微幅下滑，专业皮肤护理业务保持领先","url":"https://stock-news.laohu8.com/highlight/detail?id=1186056667","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186056667?lang=zh_cn&edition=full","pubTime":"2026-04-29 20:16","pubTimestamp":1777464967,"startTime":"0","endTime":"0","summary":"巨子生物在截至2025年12月31日止年度实现收入人民币55.19亿元，较上年同期微降0.4%；年内利润为人民币19.15亿元，同比下降7.1%。公司毛利约为人民币44.33亿元，毛利率由上年度的82.1%降至约80.3%，主要受部分产品短期销售承压及成本结构调整影响。研发投入为人民币0.89亿元，在攻关重组蛋白、透明质酸等前沿领域的同时，进一步增强了科研储备与创新能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"巨子生物2025年营收微幅下滑，专业皮肤护理业务保持领先","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630566302","title":"医美上市企业2025年业绩集体承压！爱美客、昊海生科、巨子生物等营收、净利双降","url":"https://stock-news.laohu8.com/highlight/detail?id=2630566302","media":"红星资本局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630566302?lang=zh_cn&edition=full","pubTime":"2026-04-28 20:24","pubTimestamp":1777379070,"startTime":"0","endTime":"0","summary":"红星资本局4月28日消息，近日，多家医美上市企业陆续交出2025年的“成绩单”。红星资本局注意到，多家龙头医美企业踩下业绩高增长的“急刹车”，出现营收、净利双降的情况；也有企业困于单一品牌，给业绩增长带来难题。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604283722723751.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["300896","02367","IPOS","688366"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630329652","title":"功能性护肤股2025财报全降，药妆故事为何集体失速？","url":"https://stock-news.laohu8.com/highlight/detail?id=2630329652","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630329652?lang=zh_cn&edition=full","pubTime":"2026-04-28 12:49","pubTimestamp":1777351749,"startTime":"0","endTime":"0","summary":"曾被资本追逐、被消费者追捧的功能性护肤赛道突然集体“失速”。2025年财报季披露已近尾声，回溯曾经风光无限的功能性护肤赛道，一个颇为沉重的信号浮出水面。热门“药妆”概念股集体交出下滑成绩单，行业高歌猛进的时代已告一段落。六家代表性上市公司无一幸免，但下滑的幅度与性质截然不同。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604283721978987.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604283721978987.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2488822045.USD","02367","BK1207","SG9999004311.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629048015","title":"【券商聚焦】华泰研究维持巨子生物(02367)“买入”评级 看好新品销售及医美进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2629048015","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629048015?lang=zh_cn&edition=full","pubTime":"2026-04-22 16:39","pubTimestamp":1776847155,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华泰研究发布研报指，巨子生物 核心看点在于新品推出带来的销售改善以及医美业务取得实质性进展，预期公司将于2026年重回增长轨道。该行维持对巨子生物的“买入”评级及目标价45港元。研报认为，可复美品牌自2025年6月起进入低基数阶段，新品的市场表现及其胶原系列、焦点系列等现有产品的销售节奏值得持续跟踪。盈利预测方面，华泰研究维持对巨子生物2026年至2028年的归母净利润预测，分别为19.33亿元、21.27亿元及23.02亿元人民币。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1979650","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629090949","title":"国货美妆品牌抢占线下折扣店","url":"https://stock-news.laohu8.com/highlight/detail?id=2629090949","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629090949?lang=zh_cn&edition=full","pubTime":"2026-04-22 15:24","pubTimestamp":1776842640,"startTime":"0","endTime":"0","summary":"国货美妆品牌抢占线下折扣店","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604223713962495.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604223713962495.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1997245094.SGD","02367","BK0012","LU0274383008.USD","LU2460026573.USD","LU0593848301.USD","BK0239","301371","BK0196","BK0188","603605","BK0229","BK0028","LU1146622755.USD","688363","BK1207","300957","LU2488822045.USD","IE0005HP3H50.USD","BK0070","LU1820825898.SGD","SG9999004311.SGD","BK0273","600223","LU1997245177.USD","600315"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629703720","title":"港股异动 | 巨子生物(02367)再涨超7% 央视深度探厂巨子生物 机构看好公司新产品及新业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2629703720","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629703720?lang=zh_cn&edition=full","pubTime":"2026-04-21 09:58","pubTimestamp":1776736706,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，巨子生物再涨超7%，截至发稿，涨5.8%，报31.38港元，成交额1.89亿港元。考虑到公司两款三类医疗器械“重组 I 型α1 亚型胶原蛋白冻干纤维”、“重组 I 型α1 亚型胶原蛋白及透明质酸钠复合溶液产品”陆续获批，展现其持续领先的创新能力及战略定力。后续两款医美产品的陆续商业化、以及多款妆类新品的上市值得期待，建议持续关注公司新产品和新业务进展。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431094.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02367","VXUS","LU2488822045.USD","BK4588","SG9999004311.SGD","BK1207","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186424486","title":"异动解读 | 巨子生物盘中大涨5.26%，回购注销与医美商业化预期提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1186424486","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186424486?lang=zh_cn&edition=full","pubTime":"2026-04-21 09:41","pubTimestamp":1776735662,"startTime":"0","endTime":"0","summary":"巨子生物今日盘中大涨5.26%，引起了市场的广泛关注。消息面上，公司近期迎来多重利好。一方面，公司公告注销了920万股已回购股份，回购总金额约3.22亿港元，此举有助于减少已发行股本，从而提升每股价值。另一方面，公司多款三类医疗器械注册证成功获批，医美产品即将步入商业化阶段，有望开启第二增长曲线，公司战略正向“多品牌、多品类、多渠道”转型，强化自营体系。回购注销叠加医美商业化预期，共同提振了市场对公司未来发展的信心，推动了股价在盘中的显著上涨。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174562796","title":"巨子生物回购920万股股份，涉资约3.22亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1174562796","media":"公告速递","labels":["shareholding","buyback","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174562796?lang=zh_cn&edition=full","pubTime":"2026-04-20 18:26","pubTimestamp":1776680787,"startTime":"0","endTime":"0","summary":"巨子生物控股有限公司（股票代码：02367）于2026年4月20日公告，期间自2025年12月至2026年1月间多次回购合计9,200,000股普通股，并于2026年4月20日完成注销。该批股份占回购前已发行股本约0.86%，每股回购价介乎港币33.60元至36.07元，总金额约3.22亿港元。\n回购完成后，公司已发行股本由1,070,904,000股减少至1,061,704,000股，库藏股数为零。公司同时确认已遵守香港联合交易所有限公司证券上市规则及相关法律法规。公告由执行董事兼联席公司秘书严鈺博签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628741201","title":"巨子生物(02367)注销920万股已回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2628741201","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628741201?lang=zh_cn&edition=full","pubTime":"2026-04-20 18:25","pubTimestamp":1776680738,"startTime":"0","endTime":"0","summary":"智通财经APP讯，巨子生物(02367)发布公告，于2026年4月20日，该公司注销920万股已回购股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430770.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999004311.SGD","BK1207","02367","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628714764","title":"巨子生物(02367)逆市上扬3.20% 中信建投指其医美产品即将步入商业化阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2628714764","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628714764?lang=zh_cn&edition=full","pubTime":"2026-04-20 14:43","pubTimestamp":1776667439,"startTime":"0","endTime":"0","summary":"金吾财讯 | 巨子生物 逆市上扬，截至发稿，报29.68港元，涨幅3.20%，成交额1.60亿港元。消息面上，中信建投证券研究指，巨子生物多款三类医疗器械注册证成功获批，医美产品即将步入商业化阶段，有望开启第二增长曲线。展望2026：1)重点关注III类医美器械产品上市及渠道放量；2)战略向“多品牌、多品类、多渠道”转型，强化自营体系。","market":"us","thumbnail":"https://static.szfiu.com/news/20250110/MDc3ODQ0ZjRmZjY3NDY3NWE2ZmExZWEzMjkyYmRjMmI4NjI3MTMyNDA2NzU1.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MDc3ODQ0ZjRmZjY3NDY3NWE2ZmExZWEzMjkyYmRjMmI4NjI3MTMyNDA2NzU1.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1979421","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0276","02367","601066","BK1207","LU2488822045.USD","SG9999004311.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170852498","title":"异动解读 | 巨子生物盘中大涨5.49%，年度业绩发布后市场情绪修复","url":"https://stock-news.laohu8.com/highlight/detail?id=1170852498","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170852498?lang=zh_cn&edition=full","pubTime":"2026-04-20 11:09","pubTimestamp":1776654563,"startTime":"0","endTime":"0","summary":"巨子生物今日盘中股价大幅上涨5.49%，引起了市场的广泛关注。消息面上，巨子生物近日发布了年度业绩报告。报告显示，公司全年实现营收55.19亿元，同比微降0.4%；归母净利润19.15亿元，同比下滑7.2%。这是公司上市以来首次出现营收与净利润未能延续双位数增长的情况。核心品牌可复美收入也同比有所下降。尽管业绩出现下滑，但市场认为实际降幅较为温和，且公司的绝对利润水平仍然可观。此前公司市值已出现较大幅度回落，盘面表现或反映了市场在充分消化业绩利空消息后，情绪得到修复和提振。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627025065","title":"消费板块上扬 沪上阿姨(02589)涨6.50%、奈雪的茶(02110)涨2.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627025065","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627025065?lang=zh_cn&edition=full","pubTime":"2026-04-16 10:32","pubTimestamp":1776306768,"startTime":"0","endTime":"0","summary":"金吾财讯 | 消费板块上扬，沪上阿姨 涨6.50%，奈雪的茶涨2.53%，泡泡玛特涨2.33%，巨子生物涨1.47%，上美股份涨1.19%，小米集团-W涨1.23%，名创优品涨0.97%。国信证券表示，节后以来零售及美护板块出现较多回调，主要系外围事件冲击下，大盘风险偏好下行，板块情绪走弱；同时基本面在节日错期和投放趋于谨慎，以及去年基数较高等因素下略有承压。但我们认为阶段性回调也为后续优质龙头的反弹积蓄了势能。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250110/OTZhY2RjY2M0NGRhYmE3MDgxYTI5ZDA4OTNlODY4MjM3MDk5ODc3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/OTZhY2RjY2M0NGRhYmE3MDgxYTI5ZDA4OTNlODY4MjM3MDk5ODc3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1979129","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1770036033.HKD","HXXD.SI","LU1956131251.USD","LU0211977185.USD","LU2476274720.SGD","MNSO","SG9999001093.SGD","LU0823397103.USD","LU1868837565.USD","BK1575","LU0823426480.USD","LU0348766576.USD","81810","LU2476274308.USD","BK1618","LU0348827113.USD","LU0611395673.USD","BK1502","LU2152927971.USD","LU0143863784.USD","LU1303224171.USD","LU0594300179.USD","LU0348767384.USD","LU0561508036.HKD","LU0823040885.USD","HK0000165453.HKD","LU2097828805.USD","LU2257852520.SGD","BK1587","BK1233","LU1188198961.HKD","LU0348825331.USD","LU0449509016.USD","SG9999001069.SGD","LU0052750758.USD","LU0708995583.HKD","IE0034224299.USD","09992","LU0327786744.USD","LU0320764599.SGD","LU0456827905.SGD","LU2097828631.EUR","LU0051755006.USD","LU0254981946.USD","BK1589","LU1481107354.HKD","XIACY","SGXZ86797644.SGD","BK1207","LU0231483743.USD","LU2097828474.EUR","LU0605514214.HKD","LU0117841782.USD","LU0054450605.USD","LU0244354667.USD","LU0417516902.SGD","LU1813983027.USD","BK4588","LU0823397285.USD","LU0531971595.HKD","LU1868838027.USD","LU2039709279.SGD","LU0164880469.USD","LU0084288322.USD","LU0499858438.USD","LU1251922891.USD","LU2097828714.EUR","LU0326950275.SGD","02589","LU1770034418.SGD","LU0823041008.USD","LU2488822045.USD","LU0359201885.HKD","LU0345775950.USD","LU0572944931.SGD","BK1506","LU0143863198.USD","LU1323998911.USD","02145","02367","LU0871576103.HKD","LU0235996351.USD","01810","BK1521","LU0588546209.SGD","LU0823039010.USD","LU1981816686.USD","BK1523","LU2226246903.HKD","LU0164865239.USD","LU0214875030.USD","LU2242644610.SGD","LU0359201612.USD","LU0823038988.USD","SG9999004311.SGD","LU0650527681.SGD","LU2294711473.HKD","IE0032431581.USD","BK1249","02150","LU0348735423.USD","LU0499858602.USD","LU0823413587.USD","LU0449515922.USD","LU1961090484.USD","LU0348816934.USD","LU0417516738.SGD","LU0823426308.USD","LU0502904849.HKD","LU0593848301.USD","LU0456846285.SGD","LU0918141705.HKD","LU0455707207.USD","LU0634319403.HKD","BK1607","LU1880383366.USD","LU0463099449.HKD","BK1246","BK1615","09896","BK1616","LU0164872284.USD","LU0531970944.HKD","LU0345776255.USD","LU2097828557.USD","LU1808992512.USD","LU2543165471.USD","LU1880383440.USD","LU1105468828.SGD","LU1720050803.USD","SG9999002950.SGD","SGXZ62798434.SGD","LU0700851271.USD","SG9999003461.SGD","LU0594300419.USD","LU0169518387.USD","LU0314109678.HKD","PMRTY","LU0823413660.USD","LU2399975544.HKD","HK0000286598.CNH","LU1023057109.AUD","LU1794554557.SGD","LU0359202008.SGD","LU0307460666.USD","LU0039217434.USD","LU2778985437.USD","BK4585","BK1610","LU2087589342.USD","SG9999002463.SGD","LU0540923850.HKD","MIUmain","LU0210526637.USD","LU0149721374.USD","LU0441854154.USD","LU1328277881.USD","LU1719994722.HKD","IE00B3M56506.USD","LU0348814723.USD","LU0918141887.USD","BK1193","LU0675040207.SGD","LU0797268264.HKD","LU1282648689.USD","BK1224"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625912598","title":"巨子生物(02367)委任欧阳丽妮为公司联席秘书","url":"https://stock-news.laohu8.com/highlight/detail?id=2625912598","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625912598?lang=zh_cn&edition=full","pubTime":"2026-04-08 17:29","pubTimestamp":1775640592,"startTime":"0","endTime":"0","summary":"智通财经APP讯，巨子生物(02367)发布公告，袁颕欣女士(袁女士)辞任本公司联席公司秘书及不再担任根据香港联合交易所有限公司证券上市规则第3.05条所规定的本公司授权代表，及根据香港法例第622章公司条例在香港代表接收法律程序文件而言的本公司香港法律程序文件代理人(法律程序文件代理人)，自2026年4月8日起生效。在袁女士辞任后，董事会欣然宣布委任欧阳丽妮女士(欧阳女士)为本公司公司联席秘书、授权代表及法律程序文件代理人，均自2026年4月8日起生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426023.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02367","SG9999004311.SGD","BK1207","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624650049","title":"增长失速、财富“腰斩”，医美富豪们正在失去“玻尿酸权杖”","url":"https://stock-news.laohu8.com/highlight/detail?id=2624650049","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624650049?lang=zh_cn&edition=full","pubTime":"2026-04-03 20:59","pubTimestamp":1775221178,"startTime":"0","endTime":"0","summary":"潮水退去，方知成色。2025年医美财报集体告别“高增长神话”，标志着行业正式由红利驱动的野蛮生长，步入存量博弈与逻辑重构的深度调整周期。据最新披露的业绩数据，头部企业利润出现普遍下滑。玻尿酸领域，爱美客遭遇上市后首次营收、净利双双负增长，扣非净利同比下滑超40%；昊海生科净利同比大跌40.3%。胶原蛋白赛道亦未能幸免，巨子生物录得上市后首次营收利润双降。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604033695172192.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604033695172192.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02367","SG9999004311.SGD","BK1207","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xajuzi.com","stockEarnings":[{"period":"1week","weight":-0.0572},{"period":"1month","weight":0.0273},{"period":"3month","weight":-0.1243},{"period":"6month","weight":-0.2551},{"period":"1year","weight":-0.6452},{"period":"ytd","weight":-0.119}],"compareEarnings":[{"period":"1week","weight":-0.0163},{"period":"1month","weight":0.0006},{"period":"3month","weight":-0.0227},{"period":"6month","weight":-0.041},{"period":"1year","weight":0.107},{"period":"ytd","weight":0.013}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"巨子生物控股有限公司是一家主要从事基于生物活性成分的美丽与健康产品的研发、制造及销售业务的投资控股公司。该公司的主要产品包括功效性护肤品、医用敷料等专业皮肤护理产品，以及保健食品及其他产品。该公司主要在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.063759},{"month":2,"riseRate":0.75,"avgChangeRate":0.082298},{"month":3,"riseRate":0.75,"avgChangeRate":0.049732},{"month":4,"riseRate":0.75,"avgChangeRate":0.023751},{"month":5,"riseRate":0.25,"avgChangeRate":-0.044962},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.053764},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.046799},{"month":8,"riseRate":0.666667,"avgChangeRate":0.018731},{"month":9,"riseRate":0.666667,"avgChangeRate":0.061782},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.126143},{"month":11,"riseRate":0.333333,"avgChangeRate":0.019827},{"month":12,"riseRate":0.25,"avgChangeRate":0.047101}],"exchange":"SEHK","name":"巨子生物","nameEN":"GIANT BIOGENE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"巨子生物(02367)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供巨子生物(02367)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"巨子生物,02367,巨子生物股票,巨子生物股票老虎,巨子生物股票老虎国际,巨子生物行情,巨子生物股票行情,巨子生物股价,巨子生物股市,巨子生物股票价格,巨子生物股票交易,巨子生物股票购买,巨子生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"巨子生物(02367)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供巨子生物(02367)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}